Hyperprogression in PDL1 Expressive, Recurrent Gastroesophageal-Junction Adenocarcinoma After Pembrolizumab

Cureus
doi 10.7759/cureus.4862
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Cureus, Inc.

Related search

The Role of Pembrolizumab in the Treatment of PD-L1 Expressing Gastric and Gastroesophageal Junction Adenocarcinoma

Therapeutic Advances in Gastroenterology
Gastroenterology
2019English

Radiomics Predicts Clinical Outcome in Primary Gastroesophageal Junction Adenocarcinoma Treated by Chemo/Radiotherapy and Surgery

Physics and Imaging in Radiation Oncology
Nuclear MedicineRadiologyRadiationImagingOncology
2017English

Neoadjuvant Chemoradiotherapy or Chemotherapy for Gastroesophageal Junction Adenocarcinoma: A Systematic Review and Meta-Analysis

Gastric Cancer
Cancer ResearchMedicineOncologyGastroenterology
2018English

Overview of Gastroesophageal Junction Cancers

Mini-invasive Surgery
2019English

New PDL1 Inhibitors for Non-Small Cell Lung Cancer: Focus on Pembrolizumab

OncoTargets and Therapy
OncologyPharmacology
2018English

Locally Advanced Gastroesophageal Junction Tumor: A Treatment Dilemma

Oncologist
Cancer ResearchMedicineOncology
2015English

Prm18 - Real-World Data (Rwd) Collection Alongside Early Access to Medicines Schemes (Eams) - Nivolumab in Gastric or Gastroesophageal Junction Adenocarcinoma (Gc/Gej) After Two or More Prior Therapies

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

A Multicenter Phase 2 Study of AMG 337 in Patients With MET-Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma and Other Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2018English

P51: The Expression of PD1/PDL1 in Peripheral Blood of Unexplained Recurrent Pregnancy Loss and Recurrent Implantation Failure Patients

American Journal of Reproductive Immunology
GynecologyReproductive MedicineImmunologyObstetricsAllergy
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy